Latest Marketable Securities News

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

Contact Energy reported a 12% rise in EBITDAF to $404 million for 1H25, driven by new geothermal assets and strategic contracts, while net profit fell 7% due to market volatility and acquisition costs.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

De.mem Limited has secured a strategic distribution agreement with Singapore’s Firmbase Pte Ltd to penetrate key Asian markets, including China, Indonesia, and Japan, marking its first commercial sale in China’s burgeoning home water filtration sector.

Mayne Pharma reports a robust first half of FY25 with revenues climbing to $210-$215 million and underlying EBITDA soaring by up to 300%, driven by strong performance in Women's Health.

DomaCom Limited reports a transformative quarter with executive changes, new funding facilities, and strategic initiatives including the launch of its Homeowner Equity Fund and exclusive licensing of the Bricklet Homeowner Platform.

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.

Identitii reports solid quarterly progress highlighted by a strategic new director appointment, US market expansion, and a successful $1.8 million capital raise, underpinning its path toward profitability.

Murray Cod Australia Ltd has secured a $43 million funding package from Westpac, advancing its Stanbridge site construction and expanding its biomass. The company also initiated exports to Thailand and is progressing towards entry into the Chinese market.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Global Masters Fund Limited's latest quarterly report confirms compliance with all financial obligations and highlights a recent interest rate increase on its convertible notes, supported by a robust loan-to-value ratio.